/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Theravance Biopharma, Inc. ( we, our, Theravance Biopharma or the Company ) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States ( US ) Food and Drug Administration (the FDA ) approved YUPELRI (revefenacin) inhalation solution indi…
$17.08
+$0.01 (+0.06%)
Live · 10:36 PM
The business is unprofitable at the operating level (-3.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 66.9% YoY with margins expanding 69.6pp.
Even for strong businesses, today's 16x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
16.4x earnings, 16.4x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$104M
▲ +66.9% YoY
Net Income (TTM)
$54M
▲ +287.7% YoY
Op. Margin
-4.03%
▲ +69.6pp YoY
ROIC
-1.04%
▲ +14.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$54M
▲ +2109.8% YoY
Op. Cash Flow (TTM)
$54M
▲ +2168.0% YoY
Net Debt
-$349M
Net Cash Position
Cash & Equiv.
$388M
5Y CAGR: +8.4%
Continue Research
SourceComputed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 16.4 and a price-to-free-cash-flow of 16.4, Theravance Biopharma (TBPH) trades below a two-stage DCF intrinsic value of about $24.78 per share, so at $17.08 the stock looks undervalued (45.1% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Theravance Biopharma scores 82/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $24.78 per share for TBPH, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $18.59. At today's $17.08, that puts the stock about 45.1% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Theravance Biopharma scores 82 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a -4.0% operating margin and a -1.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. TBPH currently trades below its estimated intrinsic value and scores 82/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.